<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364675">
  <stage>Registered</stage>
  <submitdate>25/07/2013</submitdate>
  <approvaldate>30/07/2013</approvaldate>
  <actrnumber>ACTRN12613000837729</actrnumber>
  <trial_identification>
    <studytitle>Intravenous magnesium as an adjunct treatment in acute exacerbations of chronic obstructive pulmonary disease.</studytitle>
    <scientifictitle>Intravenous magnesium sulphate will improve bronchodilation in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) compared to placebo.</scientifictitle>
    <utrn>U1111-1141-6451 </utrn>
    <trialacronym>MAGIC</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute exacerbations of COPD</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous magnesium sulphate 2 mmols diluted in 15mls of saline, administerered over 15minutes via infusion pump. This will be done only once. Patients will be followed up upto 2 hours post administration. Length of stay and outcome data will be collected after 1 month.</interventions>
    <comparator>Saline solution 15mls administered over 15minutes</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>FEV1 following treatment. This will be measured using bedside spirometry carried out be trained staff. </outcome>
      <timepoint>FEV1 measurements at 0, 60, 120minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>length of stay</outcome>
      <timepoint>Length of stay data will be collected 1 month post trial drug administration.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Need for NIV or mechanical ventillation.</outcome>
      <timepoint>Assessed hourly by the trial team as well as on an Ad Hoc basis by the medical team. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Known previous diagnosis of COPD, presented to ED with a primary diagnosis of acute exacerbation of COPD.</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Anyone deemed to require immediate NIV or mechanical ventilation on presentation.
Patients who are unable to carry out spirometry.
Other active problems that may be life threatening.
Hypotension.
Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible patients will be approached by members of the trial team and if agreeable by the patient, will be consented for the trial.
Randomisation and allocation will be masked to the trial staff, medical team and the patient.
Randomisation and allocation will be carried out using block randomisation by pharmacy. Numbered syringes will be provided which the trial member will use, and inform pharmacy of the syringe number. </concealment>
    <sequence>Permuted block randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>A proposed sample of 160 patients is estimated following a power calculation using previous trials as a guideline [Skorodin et al, 1995; Hughes et al, 2003; Gonzalez et al, 2006]. To detect an absolute difference in FEV1 of 0.30L with at least 80% power and an alpha error level of 5%, 80 participants were required in each treatment arm.</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2013</anticipatedstartdate>
    <actualstartdate>1/07/2013</actualstartdate>
    <anticipatedenddate>30/11/2013</anticipatedenddate>
    <actualenddate />
    <samplesize>160</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Manawatu</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Saptarshi Mukerji</primarysponsorname>
    <primarysponsoraddress>Intensive care Unit
Palmerston North Hospital
Ruahine street
Roslyn
Palmerston North
4414
</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Magnesium is used successfully to treat asthma exacerbations. Although COPD and asthma share common pathophysiology and first line therapies in acute exacerbations, little is known about the role of magnesium in acute exacerbations of COPD.
We aim to investigate whether magnesium used in conjunction with standard treatments provides better bronchodilation when compared with placebo with standard treatments. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington
6011

</ethicaddress>
      <ethicapprovaldate>19/06/2013</ethicapprovaldate>
      <hrec>13/NTA/58</hrec>
      <ethicsubmitdate>22/05/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Saptarshi Mukerji</name>
      <address>Intensive care Unit
Palmerston North Hospital
Ruahine street
Palmerston north
4414</address>
      <phone>+64223128766</phone>
      <fax />
      <email>sapimukerji@doctors.org.uk</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Saptarshi Mukerji</name>
      <address>Intensive care Unit
Palmerston North Hospital
Ruahine street
Palmerston north
4414</address>
      <phone>+64223128766</phone>
      <fax />
      <email>sapimukerji@doctors.org.uk</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Saptarshi Mukerji</name>
      <address>Intensive care Unit
Palmerston North Hospital
Ruahine street
Palmerston north
4414</address>
      <phone>+64223128766</phone>
      <fax />
      <email>sapimukerji@doctors.org.uk</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Saptarshi mukerji</name>
      <address>Intensive care Unit
Palmerston North Hospital
Ruahine street
Palmerston north
4414</address>
      <phone>+64223128766</phone>
      <fax />
      <email>sapimukerji@doctors.org.uk</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>